NO20061999L - Anvendelse av syliske anabaenopeptin-type peptider for behandling av en tilstand hvor inhibering av karboksypeptidase U er fordelaktig, nye anabaenopeptin-derivater og mellomprodukter derav - Google Patents

Anvendelse av syliske anabaenopeptin-type peptider for behandling av en tilstand hvor inhibering av karboksypeptidase U er fordelaktig, nye anabaenopeptin-derivater og mellomprodukter derav

Info

Publication number
NO20061999L
NO20061999L NO20061999A NO20061999A NO20061999L NO 20061999 L NO20061999 L NO 20061999L NO 20061999 A NO20061999 A NO 20061999A NO 20061999 A NO20061999 A NO 20061999A NO 20061999 L NO20061999 L NO 20061999L
Authority
NO
Norway
Prior art keywords
anabaenopeptin
carboxypeptidase
inhibition
intermediates
cyclic
Prior art date
Application number
NO20061999A
Other languages
English (en)
Inventor
Magnus Polla
Peter Bjorquist
Malcolm Buchanan
Marc Campitelli
Anthony Carroll
Edward Hyde
Juliette Neve
Ron Quinn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29580155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061999(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20061999L publication Critical patent/NO20061999L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)

Abstract

Anvendelse av en forbindelse med formel (I)ved en metode for fremstUling av et medikament for behandling eller forebygging av en hdelse hvor henming av karboksypeptidase U er fordelaktig; spesifiserte forbindelser med formel (1) og preparater omfattende en forbindelse med formel (1) og et farmasøytisk akseptabelt adjuvans, fortyrmingsmiddel eller bærer.
NO20061999A 2003-10-29 2006-05-04 Anvendelse av syliske anabaenopeptin-type peptider for behandling av en tilstand hvor inhibering av karboksypeptidase U er fordelaktig, nye anabaenopeptin-derivater og mellomprodukter derav NO20061999L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302853A SE0302853D0 (sv) 2003-10-29 2003-10-29 Chemical compounds
PCT/SE2004/001568 WO2005039617A1 (en) 2003-10-29 2004-10-28 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof

Publications (1)

Publication Number Publication Date
NO20061999L true NO20061999L (no) 2006-07-27

Family

ID=29580155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061999A NO20061999L (no) 2003-10-29 2006-05-04 Anvendelse av syliske anabaenopeptin-type peptider for behandling av en tilstand hvor inhibering av karboksypeptidase U er fordelaktig, nye anabaenopeptin-derivater og mellomprodukter derav

Country Status (22)

Country Link
US (1) US20080039376A1 (no)
EP (1) EP1689424A1 (no)
JP (1) JP2008501622A (no)
KR (1) KR20060132596A (no)
CN (1) CN1897963A (no)
AR (1) AR046612A1 (no)
AU (1) AU2004283643B2 (no)
BR (1) BRPI0415964A (no)
CA (1) CA2543630A1 (no)
CO (1) CO5690614A2 (no)
IL (1) IL175198A0 (no)
IS (1) IS8471A (no)
MY (1) MY143363A (no)
NO (1) NO20061999L (no)
RU (1) RU2365594C2 (no)
SA (1) SA05250463B1 (no)
SE (1) SE0302853D0 (no)
TW (1) TW200524576A (no)
UA (1) UA85199C2 (no)
UY (1) UY28585A1 (no)
WO (1) WO2005039617A1 (no)
ZA (1) ZA200603355B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10656719B2 (en) 2014-09-30 2020-05-19 Apple Inc. Dynamic input surface for electronic devices
TW201907279A (zh) 2015-09-30 2019-02-16 美商蘋果公司 具有適應性輸入列之鍵盤
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
US10732743B2 (en) 2017-07-18 2020-08-04 Apple Inc. Concealable input region for an electronic device having microperforations
WO2019040973A1 (en) 2017-09-01 2019-03-07 Alsonex Pty Ltd METHOD FOR SOLID PHASE SYNTHESIS OF CYCLIC PENTAPEPTIDES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
RU2242992C2 (ru) * 1999-05-03 2004-12-27 Астразенека Аб Фармацевтический препарат, содержащий ингибитор карбоксипептидазы u и ингибитор тромбина
ATE447557T1 (de) * 2000-08-17 2009-11-15 Pfizer Ltd Substitutuierte imidazole als tafia inhibitoren

Also Published As

Publication number Publication date
KR20060132596A (ko) 2006-12-21
IS8471A (is) 2006-05-16
WO2005039617A1 (en) 2005-05-06
AU2004283643B2 (en) 2008-07-10
CA2543630A1 (en) 2005-05-06
AR046612A1 (es) 2005-12-14
UY28585A1 (es) 2005-05-31
RU2365594C2 (ru) 2009-08-27
CN1897963A (zh) 2007-01-17
JP2008501622A (ja) 2008-01-24
MY143363A (en) 2011-04-29
BRPI0415964A (pt) 2007-01-23
SA05250463B1 (ar) 2009-02-07
SA05250463A (ar) 2005-12-03
EP1689424A1 (en) 2006-08-16
TW200524576A (en) 2005-08-01
UA85199C2 (ru) 2009-01-12
RU2006117821A (ru) 2007-12-10
US20080039376A1 (en) 2008-02-14
ZA200603355B (en) 2007-07-25
IL175198A0 (en) 2006-09-05
SE0302853D0 (sv) 2003-10-29
CO5690614A2 (es) 2006-10-31
AU2004283643A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
NO20041041L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
NO20092033L (no) Nye forbindelser
WO2004037789A3 (en) Methylene urea derivatives as raf-kinase inhibitors
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
NO20085077L (no) Nye forbindelser
DE60325074D1 (de) Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält
RU94036772A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
NO20051962L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
NO20055565L (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
NO20051263L (no) Ny anvendelse av benzotiazolderivater
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
RU94044454A (ru) Ингибитор аутоимунных заболеваний

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application